05/28/15, Exclusively for medical journalists Bayer Extends Clinical Investigation of Xarelto® for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer Cancer increases a person’s risk of venous thromboembolism (VTE) four- to seven-fold, with chemotherapy increasing the risk further by up to 6.5 times / Outside the cancer itself, blood clots are the leading cause of death in patients with cancer / Current Clinical Guidelines lack recommendations for routine VTE prevention in most ambulatory patients with cancer / Bayer and Janssen initiating CALLISTO, a multi-trial prospective clinical research initiative in the management of cancer-associated thrombosis more


A major consumer awareness campaign by Bayer HealthCare kicked off on Valentine’s Day 2015 drawing attention to the highly reliable, but little known Long Acting Contraceptives (LAC) more

Working Together to Combat River Blindness

Agreement between Bayer and the DNDi on the development of a new drug


How important to the world is the right to sexual and reproductive self-determination?

This year's International Dialogue on Population and Sustainable Development at the beginning of November was held against a special backdrop. The deadline for the Millennium Sustainable Development Goals which the United Nations had set at the turn of the millennium expires in 2015...


Bayer Clinical Trials

Information about Bayer sponsored clinical studies is available at


Facebook Banner

Follow us on Facebook



Copyright © Bayer Pharma AG